sur Relief Therapeutics Holding SA (ETR:RLF)
Relief Therapeutics Announces 2024 Financial Results and Strategic Progress
Geneva-based Relief Therapeutics Holding SA has released its 2024 financial report, highlighting significant operational and strategic milestones. The biopharmaceutical company, known for its focus on rare and unmet medical needs, showcases a strengthened financial position and key advancements in its product pipeline.
Dr. Raghuram Selvaraju, chairman of the board, emphasized the company's achievements in his annual address to shareholders. The progress of treatments such as RLF-OD032 for phenylketonuria and RLF-TD011 for epidermolysis bullosa was particularly highlighted, with crucial clinical and regulatory events anticipated in 2025.
The annual report, now available online, includes detailed pipeline updates and financial disclosures.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Relief Therapeutics Holding SA